ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
4.3300
4.3300
Range Annuel
3.2700
5.5000
Changement quotidien
-0.23%
Changement Mensuel
+28.49%
Evolution sur 6 mois
+9.62%
Changement Annuel
+9.62%
Clôture Précédente
4.3400
Ouvrir
4.3300
Plus Bas
4.3300
High
4.3300
Volume
64
Afficher le graphique complet

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

Nouvelles